Thirty subjects, matched for age and sex with no history of cerebrovascular disease, served as controls. Of this group, 20
were aPL-positive and 10 were aPL-negative. Causes of hypercoagulability other than aPL were excluded by laboratory testing. A positive test for aPL was repeated after a 6-week interval and two positive tests were required for a patient to be regarded as being aPL-positive. Levels (1) . Likewise, the recognition that the presence in the serum of antiphospholipid antibodies (aPL) is associated with venous and arterial thrombosis has led to the search for these antibodies in young patients with ischemic neurologic syndromes (2) . These antibodies may be detected in association with autoimmune diseases such as systemic lupus erythematosus (SLE) or may arise in the absence of any underlying disorder (3) . In the latter case, when thromboembolic phenomena occur, the condition is referred to as the Primary Antiphospholipid Syndrome (4) . However, 1% to 5% of healthy people may be found to have circulating antiphospholipid antibodies without being at increased risk of thromboembolism (5 3 .5 ng/mL in the aPL+CVD+ group; 0.825 ng/mL to 1.55 ng/mL in the aPL+CVD-group; 0.7 ng/mL to 1.4 ng/mL in the aPL-CVD+ group; and 0.78 ng/mL to 1.53 ng/mL in the aPL-CVD-group. aPL, antiphospholipid; CVD, cerebrovascular disease.
The median and distribution of the F1.2 values of each study group are presented in Figure 1 . Differences in the levels of F1.2 in the different patient groups were analyzed using a Kruskall Wallis one-way analysis of variance (ANOVA) for nonparametric data.
There (9) . Whereas a number of genetic causes of hypercoagulability, such as protein C and S deficiency, antithrombin III deficiency, and activated protein C resistance caused by the factor V Leiden mutation have been recognized, these are typically associated with venous thromboembolic disease (10) . Recently, two genetic abnormalities, a prothrombin gene mutation (11) 
